Abstract: The present disclosure relates to a multi-layer oral thin film comprising a first and a second matrix layer, which each contain at least one polymer, and a separation layer located between the first and the second matrix layer, wherein the separation layer comprises at least one polyethylene glycol, to a method for production of the oral thin film, and to the use thereof as a medicament.

Abstract: The present invention relates to a method for producing a multi-layer oral thin film comprising the steps of a) providing a solution, an emulsion, a foam or a suspension comprising at least one first polymer, b) processing the solution, the emulsion, the foam or the suspension from step a) in order to obtain a polymer film, c) applying a powder comprising at least one second substance, which preferably differs from the first polymer, to the polymer film, and d) forming a composite between the polymer film and the powder applied in step c), to a multi-layer oral thin film obtainable by this method, and to the use of a multi-layer oral thin film obtainable by this method as a medicament.

Abstract: The present invention relates to an oral thin film comprising a polymer matrix in the form of a solidified foam having voids, wherein the polymer matrix contains at least one active pharmaceutical ingredient, at least one first polymer which comprises a water-soluble polymer and at least one second polymer which comprises a mucoadhesive polymer having a number-average molecular weight of equal to or greater than 100,000 g/mol, a method for producing the oral thin film, and the use of such an oral thin film as a medicament.

Abstract: The present invention relates to a multi-layer thin film comprising at least two layers arranged one on top of the other which each comprise at least one polymer, these at least two layers being connected to one another by at least one stitched seam using at least one thread, and to a method for producing such a thin film and to the use thereof as a medicament.

Abstract: An apparatus and method for optically remapping projected pixels to maximize the utilization and to optimize the distribution of remapped projection pixels to achieve optimal visual performance (generally uniform resolution and luminance). A device interposed between a projector and an imaging surface for optically remapping projected pixel locations with minimal aberration. When this device is interposed between a projector and an imaging surface, it changes the terminal location of each focused pixel such that it maximally coincides with the imaging surface, which is often a surface of complex curvature and very different from the native focal surface of the projector. One implementation of the technology includes a device that uses multiple optical surfaces.

Abstract: A print component integrated circuitry package includes a number of temperature sensors where each of the plurality of the temperature sensors is disposed in a corresponding temperature region of an integrated circuitry. In an example, an analog sense bus conductively connects to all of the plurality of temperature sensors and an external sensor pad that is to connect to a corresponding print controller contact.

Abstract: Methods and systems for implementing a Jupiter aerospace mission can enable delivery of a science payload to a Jupiter orbit on a direct Earth-to-Jupiter trajectory. Solar power and use of avionics also allow a fast assembly, integration, and test process compared to past outer Solar System missions. The spacecraft can include an aerodynamic forebody, a shell, and a thermal protection system. The spacecraft can manage the radiation environment, generate solar power, and return data to Earth with a robust radio-frequency (RF) amplification and antenna gain.

Abstract: Described is an oral thin film comprising at least one matrix layer, wherein the at least one matrix layer comprises at least one pharmaceutically active agent, at least one polyvinyl alcohol and at least one polyvinyl alcohol-polyethylene glycol graft copolymer, a method for producing same, and use thereof as a medicament.

Abstract: The present invention relates to frigostable compositions suitable for iontophoretic transdermal delivery of a triptan compound. The inventive compositions include a salt of a triptan compound, preferably sumatriptan succinate, a polyamine, a dicarboxylic acid, and water or an aqueous solvent mixture, with the composition being free of monocarboxylic acids. The invention further relates to the use of the composition as an integral component of an iontophoretic patch, preferably as an anodic reservoir of the patch.

Abstract: A device for dispensing active ingredient-containing or active ingredient-carrying strips, including a housing in which a coil chamber for receiving an active ingredient-containing or active ingredient-carrying band is arranged, in which a gear transmission with a driven roller for conveying the band is mounted, and in which a separating device for separating the strips from the band is arranged. A method for dispensing active ingredient-containing or active ingredient carrying strips using such a device is also disclosed. An active ingredient-containing or active ingredient-carrying band is arranged between the driven roller and the pressure roller. A shift clutch transmission having a manually actuatable trigger element is arranged upstream of the gear transmission. The driven roller can be driven in incremental strips by the shift clutch transmission. A device and method is disclosed for dispensing active ingredient-containing or active ingredient-carrying strips with a largely equal dosage are developed.

Abstract: The present invention relates to a process for producing an oral thin film comprising microparticles, comprising the steps of: a) producing a solution comprising a hydrophobic polymer, a hydrophobic pharmaceutically active ingredient and hydrophobic solvent, b1) providing a hydrophilic polymer and providing a hydrophilic solvent immiscible with the solvent from a), or b2) providing a solution comprising a hydrophilic polymer and a hydrophilic solvent immiscible with the solvent from a), c1) mixing the solution from a) with the hydrophilic polymer from b1) followed by the addition of the hydrophilic solvent from b1) immiscible with the solvent from a) to obtain an emulsion, or c2) mixing the solution from a) and the solution from b2) to obtain an emulsion, and d) spreading and drying the emulsion from c1) or c2) to obtain an oral thin film comprising microparticles.

Abstract: Described is an oral thin film comprising at least one matrix layer, wherein the at least one matrix layer comprises at least one pharmaceutically active agent, at least one polyvinyl alcohol and at least one polyvinyl alcohol-polyethylene glycol graft copolymer, a method for producing same, and use thereof as a medicament.

Abstract: The present invention relates to iontophoretic compositions comprising a ketamine salt, a thickener in an amount to provide a viscosity of at least 500 mPas (at 20° C.), and water, and to their use for treating pain or depression. The present invention further relates to kits that comprise corresponding iontophoretic compositions and an iontophoresis device.

Abstract: The invention relates to an oral thin film, comprising a polymer matrix and ulipristal acetate as an active agent, wherein ulipristal acetate is dispersed in the polymer matrix and the polymer matrix is a matrix of water-soluble polymer selected from poly(ethylene oxide), poly(vinyl alcohol) or hydroxypropyl methylcellulose. The oral thin film is suitable as emergency contraceptive and can be administered in the oral cavity without water. It quickly disintegrates in the oral cavity wherein the active agent ulipristal acetate is mainly swallowed in undissolved form and absorbed into the gastrointestinal tract.

Abstract: The invention relates to an oral thin film, comprising a polymer matrix and at least one water-insoluble, particulate active pharmaceutical ingredient dispersed in the polymer matrix, wherein the matrix polymer is poly(ethylene oxide) having a melting point of at least 55° C., the amount of poly(ethylene oxide) having a melting point of at least 55° C. is at least 40% by weight, based on the total weight of the oral thin film, and wherein the oral thin film is obtainable by a process comprising the steps of: a) preparing a suspension comprising the matrix polymer, the at least one water-insoluble, particulate active pharmaceutical ingredient and a solvent which s water or a mixture of water and one or more organic solvents, b) casting the suspension obtained on a support or in a mold, and c) drying the suspension at a temperature above the melting temperature of the poly(ethylene oxide).

Abstract: A device for dispensing active ingredient-containing or active ingredient-carrying strips, including a housing in which a coil chamber for receiving an active ingredient-containing or active ingredient-carrying band is arranged, in which a gear transmission with a driven roller for conveying the band is mounted, and in which a separating device for separating the strips from the band is arranged. A method for dispensing active ingredient-containing or active ingredient carrying strips using such a device is also disclosed. An active ingredient-containing or active ingredient-carrying band is arranged between the driven roller and the pressure roller. A shift clutch transmission having a manually actuatable trigger element is arranged upstream of the gear transmission. The driven roller can be driven in incremental strips by the shift clutch transmission. A device and method is disclosed for dispensing active ingredient-containing or active ingredient-carrying strips with a largely equal dosage are developed.

Abstract: The invention relates to a transmucosal delivery system for idebenone, comprising an external phase, which contains at least one hydrophilic polymer, and an inner hydrophobic phase, which contains idebenone and at least one hydrophobic substance, wherein the inner hydrophobic phase is emulsified in the form of droplets in the external phase. The invention is characterized in that the inner hydrophobic phase is stabilized by at least one emulsifier in the external phase. The invention also relates to a method for producing the same and its use as a medicament.

Abstract: The present invention relates to an oral thin film comprising at least one polymer and at least one pharmaceutically active agent, wherein the concentration of the at least one pharmaceutically active agent in the oral thin film is greater than the saturation concentration of the at least one pharmaceutically active agent in the oral thin film, and wherein the oral thin film comprises at least one material which serves as crystal nucleus for the at least one pharmaceutically active agent, to a method for producing said oral thin film, and to the use of said oral thin film as a medicament.

Abstract: The present invention relates to frigostable compositions suitable for iontophoretic transdermal delivery of a triptan compound that includes: a salt of a triptan compound, preferably sumatriptan succinate, a polyamine, one or more dicarboxylic acids, 0.5 to 10.0 wt.-% (based on the total weight of the composition) of one or more monocarboxylic acids, and water or an aqueous solvent mixture. The invention further relates to the use of the composition as an integral component of an iontophoretic patch, preferably as an anodic reservoir of the patch.

Abstract: Described is an oral thin film comprising at least one matrix layer, wherein the at least one matrix layer comprises at least one pharmaceutically active agent, at least one polyvinyl alcohol and at least one polyvinyl alcohol-polyethylene glycol graft copolymer, a method for producing same, and use thereof as a medicament.